Chem. J. Chinese Universities ›› 2015, Vol. 36 ›› Issue (7): 1351.doi: 10.7503/cjcu20150091

• Physical Chemistry • Previous Articles     Next Articles

Controllable Preparation of Cu2O Microcrystals and Their Visible-light Photocatalytic Activity Toward Degradation of Methylene Blue

LI Feng1, WANG Guiyan2, ZHANG Yan1, LI Hongren1,*()   

  1. 1. Department of Chemistry, Normal College, Shenyang University, Shenyang 110044, China
    2. School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China
  • Received:2015-01-27 Online:2015-07-10 Published:2015-06-17
  • Contact: LI Hongren E-mail:hongrli@126.com
  • Supported by:
    † Supported by the PhD Research Startup Foundation of Shenyang University, China(No.11202127012)

Abstract:

Cuprous oxide microcubes were prepared by solvothermal method in glycol and water medium using copper acetate as copper source, citrate as a shape directing agent. The samples were characterized by X-ray powder diffraction(XRD), X-ray photoelectron spectroscopy(XPS), scanning electron microscopy(SEM), transmission electron microscopy(TEM) and UV-Vis diffuse reflectance spectroscopy(UV-Vis DRS). The results indicate that uniform cubic Cu2O microcrystals with the size of 0.6—1.5 μm were synthesized at 180 ℃ for 5 h by controlling the molar ratio of sodium citrate to copper acetate. The visible-driven photocatalytic activity of Cu2O microcrystals toward the degradation of methylene blue(MB) was investigated. The results show that after 100 min visible light irradiation, the degradation rate of methylene blue with initial concentration of 30 mg/L reached 98% by using 0.3 g/L Cu2O microcrystals in the presence of H2O2. The decomposition rate of MB was still above 96% even after 8 recycling uses, thus Cu2O microcrystals show high catalytic activity and excellent stability. The photocatalytic mechanism was discussed based on the active species during photocatlytic process.

Key words: Cu2O, Solvothermal method, Photocatalysis, Methylene blue(MB)

CLC Number: 

TrendMD: